LNTH vs. QDEL, NEOG, NTLA, MYGN, CLDX, ITCI, GMED, RXDX, EHC, and HALO
Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include QuidelOrtho (QDEL), Neogen (NEOG), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), Intra-Cellular Therapies (ITCI), Globus Medical (GMED), Prometheus Biosciences (RXDX), Encompass Health (EHC), and Halozyme Therapeutics (HALO). These companies are all part of the "medical" sector.
Lantheus vs.
Lantheus (NASDAQ:LNTH) and QuidelOrtho (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, community ranking, media sentiment, analyst recommendations, profitability and dividends.
97.6% of Lantheus shares are owned by institutional investors. Comparatively, 95.2% of QuidelOrtho shares are owned by institutional investors. 1.6% of Lantheus shares are owned by company insiders. Comparatively, 2.7% of QuidelOrtho shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
QuidelOrtho received 122 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.77% of users gave QuidelOrtho an outperform vote while only 65.61% of users gave Lantheus an outperform vote.
QuidelOrtho has a net margin of 16.80% compared to Lantheus' net margin of 3.00%. Lantheus' return on equity of 51.60% beat QuidelOrtho's return on equity.
In the previous week, Lantheus had 3 more articles in the media than QuidelOrtho. MarketBeat recorded 8 mentions for Lantheus and 5 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.86 beat Lantheus' score of 0.03 indicating that QuidelOrtho is being referred to more favorably in the news media.
Lantheus has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.
QuidelOrtho has higher revenue and earnings than Lantheus. QuidelOrtho is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Lantheus presently has a consensus target price of $107.33, suggesting a potential upside of 30.01%. QuidelOrtho has a consensus target price of $123.83, suggesting a potential upside of 39.00%. Given QuidelOrtho's higher possible upside, analysts plainly believe QuidelOrtho is more favorable than Lantheus.
Summary
QuidelOrtho beats Lantheus on 10 of the 19 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantheus Competitors List
